[go: up one dir, main page]

MXPA04002338A - Derivados de carbazol y su uso como antagonistas receptores del npy5. - Google Patents

Derivados de carbazol y su uso como antagonistas receptores del npy5.

Info

Publication number
MXPA04002338A
MXPA04002338A MXPA04002338A MXPA04002338A MXPA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
carbazole derivatives
npy5 receptor
formula
npy5
Prior art date
Application number
MXPA04002338A
Other languages
English (en)
Inventor
Michael Block Howard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04002338A publication Critical patent/MXPA04002338A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe el uso de un compuesto de la formula (I) en la obtencion de un medicamento para el tratamiento de un animal de sangre caliente de los desordenes regulados por el receptor del neuropeptido Y5 (I), en donde R1, R2, R3 y X1- X6 son como se definen en la presente o una sal aceptable farmaceuticamente, pro-farmaco o solvato del mismo. Las composiciones farmaceuticas, los metodos y los procedimientos para la preparacion de los compuestos de la formula (I) son tambien descritos.
MXPA04002338A 2001-09-11 2002-09-09 Derivados de carbazol y su uso como antagonistas receptores del npy5. MXPA04002338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121941.9A GB0121941D0 (en) 2001-09-11 2001-09-11 Chemical compounds
PCT/GB2002/004109 WO2003022849A1 (en) 2001-09-11 2002-09-09 Carbazole derivatives and their use as npy5 receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA04002338A true MXPA04002338A (es) 2004-06-29

Family

ID=9921890

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002338A MXPA04002338A (es) 2001-09-11 2002-09-09 Derivados de carbazol y su uso como antagonistas receptores del npy5.

Country Status (14)

Country Link
US (1) US7408064B2 (es)
EP (1) EP1427729A1 (es)
JP (1) JP2005516892A (es)
KR (1) KR20040036939A (es)
CN (1) CN1653067A (es)
BR (1) BR0212484A (es)
CA (1) CA2459973A1 (es)
GB (1) GB0121941D0 (es)
IL (1) IL160771A0 (es)
MX (1) MXPA04002338A (es)
NO (1) NO20041008L (es)
NZ (1) NZ531678A (es)
WO (1) WO2003022849A1 (es)
ZA (1) ZA200401956B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100503607C (zh) * 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7732447B2 (en) 2006-06-22 2010-06-08 Cephalon, Inc. Fused [d]pyridazin-7-ones
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR101710732B1 (ko) 2008-06-11 2017-02-27 제넨테크, 인크. 디아자카르바졸 및 사용 방법
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111850A (en) 1977-02-16 1978-09-05 Amp Incorporated Organic photoconductors and methods
FR2546163B1 (fr) 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
JPS6079348A (ja) 1983-10-06 1985-05-07 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
US5234942A (en) 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
EP0304223A3 (en) * 1987-08-17 1990-10-24 Merck & Co. Inc. Beta-carbolines as cholecy-stokinin and gastrin antagonist
US5223509A (en) * 1987-08-17 1993-06-29 Merck & Co., Inc. β-carbolines as cholecystokinin and gastrin antagonists
EP0342433A3 (en) 1988-05-19 1991-06-19 American Cyanamid Company Substituted dibenzothiaphenes
CA1285827C (en) * 1988-06-03 1991-07-09 Richard Barr Life step stabilizer
DK0381422T3 (da) 1989-02-02 1997-03-10 Yamanouchi Pharma Co Ltd Tetrahydrobenzimidazolderivater
US5254135A (en) 1989-10-20 1993-10-19 L'oreal Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use
IE904560A1 (en) * 1989-12-18 1991-06-19 Merck & Co Inc New benzodiazepine analogs
PT98927A (pt) 1990-09-13 1992-07-31 Beecham Group Plc Processo para a preparacao de piridil-indolil-ureias
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
CZ85994A3 (en) 1991-10-16 1994-12-15 Richardson Vicks Inc Pharmaceutical preparation for local use and exhibiting increased penetration through skin
GB9203637D0 (en) 1992-02-19 1992-04-08 Smithkline Beecham Plc Novel treatment
WO1993018026A1 (en) 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
NZ290936A (en) 1994-09-30 1998-01-26 Pfizer 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997020821A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl derivatives
AU715233B2 (en) 1996-01-10 2000-01-20 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
JP4331264B2 (ja) 1996-07-08 2009-09-16 協和発酵キリン株式会社 カルシウムレセプター活性化合物
JP3679207B2 (ja) 1996-09-12 2005-08-03 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
AU5410498A (en) 1996-12-12 1998-07-03 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
CA2251580A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
JP2000510164A (ja) 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
AU6852898A (en) 1997-04-17 1998-11-11 Takeda Chemical Industries Ltd. Thermogenic composition and benzazepine thermogenics
FR2763942B1 (fr) 1997-06-02 2002-09-13 Asepta Sa Lab Nouveau procede de preparation de n-acylaminoacides
AU735249B2 (en) 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
JPH11130817A (ja) 1997-08-28 1999-05-18 Junji Kido ビニル系重合体及びそれを用いたエレクトロルミネッセンス素子
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11174077A (ja) 1997-12-09 1999-07-02 Hokuriku Electric Ind Co Ltd 加速度検出装置
DE1041982T1 (de) 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
PT1042305E (pt) 1997-12-22 2005-10-31 Bayer Pharmaceuticals Corp Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
AU757488B2 (en) 1998-03-25 2003-02-20 Bristol-Myers Squibb Company Imidazolone anorectic agents: III. heteroaryl derivatives
EP1066257A2 (en) 1998-03-26 2001-01-10 Sugen, Inc. Heterocylic classes of compounds for the modulating tyrosine protein kinase
AU3220299A (en) 1998-04-02 1999-10-25 Neurogen Corporation Substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives:selective neuropeptide y receptor ligands
WO1999051600A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES
AUPP285898A0 (en) 1998-04-07 1998-04-30 Fujisawa Pharmaceutical Co., Ltd. Amido derivatives
RU2219167C2 (ru) 1998-04-29 2003-12-20 Орто-Макнейл Фармасьютикал, Инк. N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств
WO1999064394A1 (en) 1998-06-08 1999-12-16 Schering Corporation Neuropeptide y5 receptor antagonists
DE69931975T2 (de) 1998-08-07 2006-10-05 Applied Research Systems Ars Holding N.V. FSH Mimetika zur Behandlung von Infertilität
EP1119543B1 (en) 1998-10-07 2004-12-15 Ortho-McNeil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor
WO2000023425A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1184373A4 (en) * 1999-04-20 2004-10-20 Meiji Seika Kaisha TRICYCLIC CONNECTIONS
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
GB0011013D0 (en) 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
WO2001090120A2 (en) 2000-05-19 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the evx1 gene
BR0116388A (pt) * 2000-12-22 2003-09-30 Astrazeneca Ab Composto, processo para preparar um composto, composição farmacêutica e método para tratar, em um animal de sangue quente, distúrbios de alimentação e uso de um composto
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
JP2005516892A (ja) 2005-06-09
GB0121941D0 (en) 2001-10-31
NO20041008L (no) 2004-03-10
ZA200401956B (en) 2005-04-15
BR0212484A (pt) 2004-08-24
KR20040036939A (ko) 2004-05-03
CA2459973A1 (en) 2003-03-20
EP1427729A1 (en) 2004-06-16
US20050065157A1 (en) 2005-03-24
IL160771A0 (en) 2004-08-31
CN1653067A (zh) 2005-08-10
NZ531678A (en) 2005-09-30
WO2003022849A1 (en) 2003-03-20
US7408064B2 (en) 2008-08-05

Similar Documents

Publication Publication Date Title
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MY130803A (en) New quinuclidine amide derivatives
TW200621762A (en) Novel compounds
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
MXPA03005464A (es) Agentes antivirales.
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
MY138352A (en) Benzothiazole derivatives
JO2371B1 (en) 4-phenyl-pyridine derivatives
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
GB0112348D0 (en) Compounds
SE0104341D0 (sv) New use
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
ATE386725T1 (de) Heterocyclylverbindungen
GB0109122D0 (en) Novel compounds
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
CA2354606A1 (en) Azabicycloalkane derivatives and therapeutic uses thereof
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
WO2005118579A3 (en) Thiazole derivatives as chemokine receptor antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal